The rapid advancement of Cell and Gene Therapy (CGT) has positioned plasmid DNA (pDNA) as a critical therapeutic cornerstone. Whether utilized as an active pharmaceutical ingredient in DNA vaccines, a template for mRNA therapeutics, or a vital raw material for viral vector production, there is a constant demand for pDNA production.
However, the biopharmaceutical industry faces a significant bottleneck: consistently manufacturing high-yield, high-purity pDNA at scale. Navigating these complexities requires more than a traditional vendor; it requires a strategic Contract Development and Manufacturing Organization (CDMO) partner capable of delivering operational agility and manufacturing excellence.
Best in class pDNA product with our pART platform
Richter BioLogics developed its proprietary pART production platform process.
Leveraging over 35 years of expertise in E. coli fermentation, pART delivers highly purified, supercoiled (sc) pDNA, the therapeutically preferred isoform, at exceptional concentrations. The process guarantees ≥95% purity for plasmid sizes for the whole range of typical plasmid sizes. By optimizing upstream processing (USP), midstream cell lysis and clarification (MSP), and advanced downstream purification (DSP), we eliminate process friction and ensure reproducible, best-in-class results.
Seamless Scalability and End-to-End Integration
Richter BioLogics manufactures pDNA product from clinical phases to commercial scale through a fully integrated, one-stop-shop service model. You either start from scratch or we transfer your process to our facilities.
- Ready-to-Use, High-Yield pDNA Production Platform offers:
- Plug-and-Play QC Panel
- Compatible with Any Construct or Strain
- Speed - GMP Material Supply Within 3 - 6 Months
- From Clinical to Commercial
- Customizable Manufacturing Volume (10L - 1,000L)
Our harmonized processes facilitate seamless scalability, successfully accommodating fermentation volumes from 10L up to 1,000L. Supported by 3 multipurpose facilities, we provide the flexible capacity necessary to accelerate your time-to-market without compromising on quality or efficiency.
Uncompromising Regulatory Excellence
Developing the therapies of tomorrow requires navigating today’s stringent global regulatory frameworks. Our commitment to quality is validated by our extensive regulatory credentials. Our GMP-certified facilities have been successfully inspected and approved by key global regulatory bodies, including the EMA, FDA, PMDA, ANVISA, Health Canada, and MFDS. We ensure that every pDNA project remains audit-ready and compliant, securing your supply chain from concept to commercialization.
A Customer-Centric Partnership Approach
Being customer-centric means we place our clients’ product success at the heart of everything we do. We understand that choosing a CDMO is about finding a true partner. Richter BioLogics operates as a direct extension of your team, utilizing highly qualified project managers and data-driven digital tools to keep your project aligned with business priorities. Through transparent communication and a “Person in Plant” philosophy, we foster mutual respect and hands-on engagement.
Secure Your Supply Chain for the Therapies of Tomorrow
The dynamic landscape of CGT demands innovation, precision, and uncompromising quality. Choosing Richter BioLogics is a strategic decision that offers a unique combination of specialized expertise in microbial manufacturing, end-to-end service integration, and a profound commitment to partnership.
Trust our proven pART platform to secure your supply chain and elevate your therapeutic breakthroughs. Contact our sales team today to learn how Richter BioLogics can drive your pDNA project forward.